Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kara Tsi
Institution:
Cedars-Sinai Smidt Heart Institute
Observed institutions:
Cedars-Sinai Medical Center,
Cedars-Sinai Smidt Heart Institute
ORCID:
0009-0003-8593-7037
Observed ORCID:
0009-0003-8593-7037
OpenAlex ID:
A5094010768
Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanism
2024
·
Alessandra Ciullo
, Liang Li
, et al.
·
European Heart Journal
·
22
PDF
Augmentation of DNA exonuclease TREX1 in macrophages as a therapy for cardiac ischemic injury
2025
·
Ahmed Gamal-Eldin Ibrahim
, Alessandra Ciullo
, et al.
·
Science Translational Medicine
·
12
PDF
Macrophages Contribute to Cardiac Fibrosis and Diastolic Dysfunction in Systemic Sclerosis
2024
·
Xaviar M. Jones
, Russell G. Rogers
, et al.
·
JACC Basic to Translational Science
·
10
Intravenous and oral administration of the synthetic RNA drug, TY1, reverses heart failure with preserved ejection fraction in mice
2024
·
Kazutaka Miyamoto
, Xaviar M. Jones
, et al.
·
Basic Research in Cardiology
·
6
PDF
Oral Bioavailability of a Noncoding RNA Drug, TY1, That Acts on Macrophages
2025
·
Shukuro Yamaguchi
, Kazutaka Miyamoto
, et al.
·
Journal of Extracellular Biology
·
5
PDF
Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS/STING pathway
2026
·
Xaviar M. Jones
, Salwa Soussi
, et al.
·
JCI Insight
A Novel Multi-Target Approach for Cardiometabolic HFpEF: Preclinical Evidence for Semaglutide and TY1 Combination Therapy
2025
·
Mahmoud Elbatreek
, Liz Sanchez
, et al.
·
Journal of Molecular and Cellular Cardiology Plus
Semaglutide plus novel Noncoding RNA drug TY1 Exert Synergistic Benefits Against Diastolic Dysfunction in HFpEF
2025
·
Mahmoud H. Elbatreek
, Zhen Li
, et al.
·
Journal of Molecular and Cellular Cardiology Plus
Show more works
View as search
Works count:
8
Citation count:
55
H-index:
5
I10-index:
3
Year
Topic
Type
